KPV — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

KPV

Also known as: Lys-Pro-Val, Lysine-Proline-Valine, α-MSH(11-13), alpha-MSH C-terminal tripeptide, alpha-MSH 11-13

Anti-inflammatory tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH)

Research chemicalLast updated: October 31, 2026Based on 40 peer-reviewed studies

What it is

KPV is a short peptide used for gut inflammation and skin conditions, including ulcerative colitis and wound healing. It works as a local anti-inflammatory agent, calming the immune response without the systemic side effects of steroids. Not FDA-approved; the FDA has restricted it from compounding; most evidence from animal models and cell studies.

The scientific side

KPV (Lys-Pro-Val) is the C-terminal tripeptide (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH), which is itself derived from proopiomelanocortin (POMC). KPV retains the anti-inflammatory capacity of the full α-MSH hormone but lacks the central pharmacophore required for binding to known melanocortin receptors (MC-Rs) and lacks pigmentary activity. At the molecular level, KPV inhibits NF-κB activation, suppresses MAP kinase inflammatory signaling pathways, and reduces pro-inflammatory cytokine secretion including IL-1β, TNF-α, IL-6, and IL-8. KPV is transported into intestinal epithelial cells and immune cells via the oligopeptide transporter PepT1 (also known as SLC15A1), which is normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. In human keratinocytes, KPV signals via rapid intracellular calcium mobilization rather than cyclic AMP elevation. KPV has also demonstrated direct antimicrobial effects against Staphylococcus aureus and Candida albicans, potentially mediated by increases in cellular cAMP in target pathogens. One abstract notes that KPV, unlike full α-MSH, did not elicit inhibitory effects on basophil activation, which was attributed to KPV lacking the central pharmacophore of α-MSH. In the context of vascular calcification, KPV-RAPA nanoparticles were found to inhibit inflammatory responses. KPV has also been shown to inhibit ROS production and ROS-mediated caspase-1 activation, blocking pyroptosis in keratinocytes exposed to fine particulate matter.

Class: Anti-inflammatory tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH)

Administration & storage

Administration
Oral administration via drinking water in mouse colitis models (PMID: 18061177)Delivery to the colon via nanoparticles in a polysaccharide hydrogelin a mouse colitis model (PMID: 19909746)Oral administration via HA-functionalized nanoparticles in chitosan/alginate hydrogel (PMID: 28143741)Oral administration via self-immolative prodrug conjugate nanoparticles (PMID: 41533788)Topical/mucosal administration to gingival mucosa in rats via in situ hydrogel (PMID: 34846053)Transdermal delivery via iontophoresis and/or microneedles across dermatomed human skin (PMID: 28343991)In vitro cell culture (PMID: 4007346718061177151020921067058511073109)
Storage
A stability-indicating HPLC method was developed for KPV in aqueous solutions and skin homogenates; under stress conditions (acid, alkali, hydrogen peroxide), KPV yielded lys-pro-diketopiperazine as a major degradation product. No specific storage temperature or conditions for KPV as a bulk compound are described in the reviewed abstracts.
Cautions
KPV has been studied primarily in animal models and in vitro; no human pharmacokinetic or clinical safety data are reported in the reviewed literature.,KPV is subject to chemical degradation under acidic, alkaline, and oxidative (hydrogen peroxide) conditions, yielding lys-pro-diketopiperazine as a major degradation product; formulation stability should be verified.,The largely unregulated supply chain for compounded peptides raises concerns about product mislabeling or contamination; purity of non-pharmaceutical-grade KPV cannot be assumed.,Long-term safety and systemic risks of KPV have not been defined in the reviewed literature; peptides in general carry potential risks including cardiovascular strain and other adverse effects when used outside controlled research settings.,Sterile technique is essential for any injectable or mucosal preparation to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification